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Introduction
Pancreatic cancer is considered among the most aggressive and the least curable of all human malignancies. The five year survival rate is less than 5% because of its highly malignant phenotype, which is characterised by rapid progression, early metastasis and limited response to chemotherapy and radiotherapy [1] . Surgery is considered the only curative option; however, 80-90% of patients are diagnosed too late to permit surgical intervention because of distant metastases or major vessel involvement [2, 3] . For these patients, treatment is confined to chemo-and/or radio-therapy. Even after surgery, the 5-year survival rate is only 10% to 25% due to a high rate of local recurrence, peritoneal dissemination, liver metastases, and lymph node recurrence [4] . Currently gemcitabine-based chemotherapy, which targets rapidly replicating cells, remains the main form of treatment for patients with advanced pancreatic cancer and as adjuvant therapy after surgical resection, but the response is varied, with only modest improvements in survival [5] . Tumour progression eventually occurs as cancer cells develop increasing resistance to chemotherapy. There is therefore an urgent need to improve treatment outcomes through the development of more effective chemotherapeutic regimens based on an increased understanding of the molecular mechanisms involved in the development of pancreatic adenocarcinoma.
Pancreatic cancer develops as a result of a series of genetic mutations, and progresses from non-invasive tumours to invasive and metastatic cancers [6] . The most frequent mutations in pancreatic cancer involve the Kras gene and are observed in more than 95% of cases. The product of the Kras gene is a protein of 21 kDa (p21), which binds to and activates the p21-activated kinases (PAKs). The PAK family of serine/threonine kinases are not only important in carcinogenesis, but also are major regulators of cytoskeletal dynamics, with significant roles in cell proliferation, survival and motility [7] . PAKs are divided into 2 groups (PAKs 1, 2 and 3, and PAKs 4, 5 and 6) based on sequence homologies. The PAK4 gene is amplified in some pancreatic cancers and amplification is associated with significantly higher kinase activity of the PAK4 protein [8] . PAK4 stimulates pancreatic cell migration/invasion [9] . In pancreatic cancer cells increased expression and activation of PAK1 is correlated with increased expression of MUC13, which stimulates xenograft growth of pancreatic cancer cells [10] . Conversely SMAD4 induces pancreatic cancer cell death by suppression of PAK1 [11] .
Glaucarubinone, a quassinoid natural product first isolated from the seeds of Simarouba glauca, and later from numerous other species in the family Simaroubaceae, was originally developed as an antimalarial drug [12] . Although glaucarubinone has been shown to possess anti-cancer activity [13, 14] , the mechanisms involved are not fully understood. A recent report indicated that quassinoids including glaucarubinone inhibited the transcription factor activator protein-1 (AP-1), independently of their cytotoxicity [15] . Several independent lines of evidence suggest that glaucarubinone may act, at least in part, via inhibition of pathways involving PAK1 [16] Thus suppression of PAK1 causes death in malaria parasites [17] , as does glaucarubinone. We have previously shown that glaucarubinone inactivates NF-kappaB [15] , whose activation requires PAK1. Furthermore, glaucarubinone may extend the lifespan of C. elegans, which is also increased by down-regulation of PAK1 [18] . Nearly 100% cases of pancreatic cancer carry mutations in KRas, and PAKs are activated by and act downstream of KRas. To determine the effects of glaucarubinone and/or gemcitabine on pancreatic cancer growth and the mechanism involved, we investigated the effects of glaucarubinone and/or gemcitabine on the growth and migration of pancreatic cancer cell lines, and on the expression and activation of PAK1 and PAK4 in the same cell lines in vitro and as xenografts in nude mice.
Material and methods

Cells and reagents
The human PANC-1 and MiaPaCa-2 pancreatic cancer cell lines (purchased from SigmaAldrich, Sydney, Australia) and the murine PAN02 pancreatic cancer cell line (obtained from National Cancer Institute (Frederick, MD, USA)) were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% FBS (fetal bovine serum; HyClone Laboratories Inc, Melbourne, Australia) in a 37 ºC incubator in a humidified atmosphere of 5% CO 2 . Cells tested negative for mycoplasma, and were passaged not more than 30 times.
Glaucarubinone, prepared as prescribed previously [15] , was obtained from the National Cancer Institute (NCI) Chemotherapeutics Repository, and gemcitabine was purchased from Sigma-Aldrich.
Cell proliferation
Cell proliferation was measured using a 3 H-thymidine incorporation assay. Cells were seeded in a 96-well plate at 5×10 3 cells/well in DMEM containing 10% FBS, with 1µCi/well were harvested and radioactivity detected as described above. Each treatment was done in duplicate and three independent experiments were collated.
Migration and invasion assay
Cell migration and invasion was measured using a Transwell Boyden Chamber assay as described previously [19] . Membranes (8-µm pore size, Becton Dickinson, NJ) were coated with 3µg of human fibronectin on the lower surfaces and placed into a 24-well plate containing 600 µl/well serum-free DMEM containing 0.1% bovine serum albumin (BSA).
Cells were added to the upper chambers at 5x10 
Combination index
The combined effects of gemcitabine and glaucarubinone were evaluated using the ChouTalalay method [20, 21] 
Murine xenograft study
All mouse experiments were approved by the Austin Health Animal Research Ethics
Committee. SCID mice were purchased from the Animal Resource Centre (Perth, Australia), and housed in micro-isolators. For the xenograft studies, 5x10 6 PANC-1 and MiaPaCa-2 cells in 100 µl DMEM were subcutaneously injected into the opposite flanks of each of 20 mice (6 weeks old). Tumor dimensions were measured every other day using callipers, and volumes calculated using the formula w 2 x L/2, where w and L are the shortest and longest tumor diameters, respectively. Mice were divided into four groups (5 mice per group) as follows: 1.
Control, receiving intraperitoneal (i.p.) injection of saline every other day; 2. Glaucarubinone, receiving glaucarubinone (i.p.) every other day at 1 mg/kg for the first week followed by 2 mg/kg for the remaining 5 weeks; 3. Gemcitabine, receiving gemcitabine (i.p.) weekly at 20 mg/kg for 6 weeks; 4. Glaucarubinone and gemcitabine, receiving gemcitabine weekly as for group 3, and glaucarubinone every other day as for group 2. The dose chosen for glaucarubinone was based on preliminary experiments where the maximal amount that could be tolerated by mice without significant toxicity was 2 mg/kg. Mice were sacrificed on day 43, and tumor tissues were weighed, and extracted for immunoblotting or fixed and paraffinembedded for immunostaining.
Western blot
Cells, treated with glaucarubinone and/or gemcitabine as indicated in the text, were lysed in SDS sample buffer and subjected to SDS-PAGE for immunoblotting. Proteins were detected with antibodies against PAK1, and its active form, phospho-PAK1 (Santa Cruz, USA), PAK4
and its active form, phospho-PAK4, and GAPDH (Genesearch, Melbourne, Australia). The bound antibodies were visualized using ECL reagents (GE Healthcare, Amersham, England), and the density of each band was analysed using Multigauge software (Berthold, Bundoora, Australia). Proteins were extracted from tumor tissues by homogenising and sonicating in 1%
Triton X100 lysis buffer (50 mM HEPES, 150 mM NaCl, 10 mM EDTA, 10 mM Na 4 P 2 O 7 , 100 mM NaF, 5 µg/ml aprotinin, 5 µg/ml leupeptin and 1 mM PMSF), subjected to SDS-PAGE, and immunoblotted with the antibodies indicated in the text.
Immunohistochemistry (IHC)
The tumor tissues were stained with Ki67 antibody (Dakocytomation, Sydney, Australia) for proliferation, and active caspase 3 antibody (R&D systems, Minneapolis, MN) for apoptosis.
The tumor tissues were imaged using a Nikon Coolscope and the ratio of positive cells to the total number of cells in each field calculated using the Image Pro-Plus 6.0 image analysis program (Media Cybernetics Inc., Silver Spring, MD).
Statistical analysis
All values are expressed as means + standard error. Results were analyzed by one-way analysis of variance or t-test as appropriate with the program SigmaStat (SPSS, Chicago, IL).
Differences between two means with p < 0.05 were considered significant.
Results
Glaucarubinone inhibited pancreatic cancer cell proliferation and migration.
The effect of glaucarubinone on pancreatic cancer cell proliferation was determined using a 3 H-thymidine-incorporation assay. Glaucarubinone inhibited the proliferation of three pancreatic cancer cell lines in a dose-dependent manner ( Fig. 1A-C) . The IC 50 values were 300 nM for PANC-1, 58 nM for MiaPaCa-2, and 960 nM for PAN02 ( Table 1 ). The effect of glaucarubinone on pancreatic cancer cell migration/invasion was measured using a Boyden
Chamber assay. Similarly, glaucarubinone inhibited the migration/invasion of these cell lines in a dose-dependent manner ( Fig. 1A-C) . The IC 50 values were 210 nM for PANC-1, 44 nM for MiaPaCa-2, and 220 nM for PAN02 (Table 1) . At the same concentrations used for the proliferation assay, glaucarubinone did not inhibit survival in the absence of serum for any of the 3 cell lines tested ( Supplementary Fig.1 ).
Increasing sensitivity to glaucarubinone correlated with reduced amounts of active PAK1 and PAK4.
The IC 50 values for inhibition of proliferation and migration by glaucarubinone varied among three pancreatic cancer cell lines. MiaPaCa-2 was most sensitive to glaucarubinone with the lowest IC 50 values for both proliferation and migration, while PAN02 was least sensitive to glaucarubinone with the highest IC 50 values (Table 1) . Similar trends were observed in the expression and activation of PAK1 in untreated pancreatic cancer cell lines (Fig. 1D) , as MiaPaCa-2 had the lowest expression of PAK1 and the lowest concentration of the active form of PAK1 (phospho-PAK1 (pPAK1)), while PAN02 had the highest expression of both PAK1 and phospho-PAK1 (Fig. 1D) . Although there was no significant difference in PAK4 expression among untreated pancreatic cancer cell lines, MiaPaCa-2 had the lowest expression of the active form of PAK4 (phospho-PAK4 (pPAK4)), while PAN02 had the highest expression of phospho-PAK4 (Fig 1E) . The matching patterns of IC 50 values and PAK1/4 activities suggested that the sensitivities of these pancreatic cancer cells to glaucarubinone might be correlated with the amount of active PAK1 and PAK4. In fact the IC 50 values for inhibition of proliferation by glaucarubinone were significantly correlated with the amount of pPAK4 (Fig. 1G) , and the correlation in the case of pPAK1 (Fig. 1F) approached significance. No correlation was observed between the IC 50 values for inhibition of proliferation and the total amounts of PAK1 or PAK4, or between the IC 50 values for inhibition of migration and either the amounts of pPAK1 or pPAK4, or the total amounts of PAK1 or PAK4 (data not shown).
Glaucarubinone and gemcitabine synergistically inhibited pancreatic cancer cell growth.
The combined effects of glaucarubinone and gemcitabine on proliferation were measured by incubation of the pancreatic cancer cell lines with different concentrations of gemcitabine, alone or in combination with glaucarubinone, at concentrations close to the IC 50 values for glaucarubinone given in Table 1 . Gemcitabine on its own inhibited proliferation in the three pancreatic cancer cell lines in a dose-dependent manner ( Fig. 2A-C) . The IC 50 values for gemcitabine were 40 nM for PANC-1, 46 nM for MiaPaCa-2, and 100 nM for PAN02 (Table   1) . A further reduction of proliferation was observed in all three cell lines when the cells were treated with glaucarubinone and gemcitabine in combination, compared to gemcitabine alone ( Fig. 2A-C) . The combined effect of glaucarubinone and gemcitabine was shown to be synergistic rather than additive when using the Chou-Talalay method analysed [20] ( Supplementary Fig. 2 ). These results demonstrated that glaucarubinone and gemcitabine synergistically inhibited pancreatic cancer cell growth.
Inhibition of pancreatic cancer cell growth by glaucarubinone and gemcitabine was associated with reduced amounts of active PAK1 and PAK4.
To investigate the mechanism involved in the inhibition of pancreatic cancer cell growth by gluacarubinone and gemcitabine, the effects of the two drugs on the expression and activity of PAK1 and PAK4 were determined. The human pancreatic cancer cell lines PANC-1 and MiaPaCa-2 were treated with glaucarubinone and/or gemcitabine at concentrations close to their IC 50 values ( Table 1 ). The total amounts of PAK1 and PAK4, and the amounts of active phospho-PAK1 and phospho-PAK4, were measured by Western blotting. In MiaPaCa-2 cells, glaucarubinone significantly decreased the amount of both active PAK1 (Fig. 3A ) and active PAK4 (Fig. 3B ) without affecting the expression of either PAK1 or PAK4. Gemcitabine alone had no significant effect on the amount of either active PAK1 (Fig. 3A) or active PAK4
( Fig. 3B) , which stayed so even with gemcitabine at 100 nM that was twice more than its IC 50 in a dose dependent assay (data not shown). However the amounts of both active PAK1 and PAK4 were further decreased by the combination of glaucarubinone and gemcitabine (Fig.   3A&B ). Similar results were obtained in PANC-1 cells treated with glaucarubinone and gemcitabine ( Fig. 3C&D ), but not with glaucarubinone alone. These data suggested that glaucarubinone and gemcitabine synergistically reduced pancreatic cancer cell growth by reducing the amounts of active PAK1 and PAK4.
Glaucarubinone and gemcitabine inhibited pancreatic cancer cell xenograft growth in
vivo by decreasing proliferation.
To were significantly reduced by glaucarubinone or gemcitabine alone to 28% and 44%, respectively, of untreated control tumors (Fig. 4C) . The combined treatment with glaucarubinone and gemcitabine also reduced the tumor weight to 20% of control, and the reduction was significantly greater than for gemcitabine-treated tumors (p<0.05, Fig. 4C ), but not for glaucarubinone-treated tumors (Fig. 4C) . Neither glaucarubinone nor gemcitabine alone had any significant effect on the tumor growth of PANC-1 xenografts (Fig. 4B&D) .
However, the combined treatment with glaucarubinone and gemcitabine significantly reduced the tumor volume from day 32 (p<0.05, Fig. 4B ), and the tumor weight to 37% of control (p<0.05, Fig. 4D ).
Proliferation and apoptosis of cells within the xenografted tumors were measured by immunohistochemistry. For MiaPaCa-2 cells, there was no significant difference in proliferation between untreated control tumors and tumors treated with either glaucarubinone or gemcitabine alone. However the proliferation in tumors from the group treated with glaucarubinone and gemcitabine in combination was reduced to 75% of the value for untreated control tumors (Fig. 5A, B) . There was no significant difference in apoptosis between tumors from the four groups (Fig. 5C, D) . These results indicate that glaucarubinone and gemcitabine synergistically inhibited pancreatic cancer growth in vivo by reducing proliferation.
Glaucarubinone and gemcitabine decreased the amounts of active PAK1 and PAK4 in vivo.
To determine the effects of glaucarubinone and gemcitabine on the expression and activity of PAK1 and PAK4, proteins were extracted from tumor tissues. The total concentrations of PAK1 and PAK4, and of active pPAK1 and pPAK4, were measured by Western blotting as described in the Material and Methods section. Similarly to the in vitro results, glaucarubinone alone decreased the amounts of active PAK1 in both MiaPaCa-2 and PANC-1 tumors, without affecting the expression of PAK1 (Fig. 6A&C) . Treatment with glaucarubinone and gemcitabine in combination further reduced the amounts of active PAK1
in both MiaPaCa-2 and PANC-1 tumors (Fig. 6A&C) . However, in contrast to the in vitro results, only treatment with glaucarubinone and gemcitabine in combination significantly reduced the amounts of active PAK4 in both MiaPaCa-2 and PANC-1 tumors (Fig. 6B&D ).
Neither glaucarubinone nor gemcitabine affected the amount of active PAK4 in MiaPaCa-2 tumors (Fig. 6B) . While gemcitabine reduced the amount of active PAK4 in PANC-1 tumors, glaucarubinone had no significant effect on the amount of active PAK4 in PANC-1 tumors (Fig. 6D) . These results suggested that glaucarubinone and gemcitabine synergistically reduced pancreatic cancer growth in vivo at least partially through a reduction in the amounts of active PAK1 and PAK4.
Discussion
In As summarised in the Introduction, PAKs are a likely target for the anti-cancer activity of quassinoids. Almost 100% of pancreatic cancers carry KRas mutations [6] , and PAKs are among the major downstream effectors of Ras. In particular, PAK1 is required for Rasinduced malignant transformation of cells [22] , and PAK4 activity is necessary for Rasdriven, anchorage-independent growth of colorectal cancer cells [23] . We therefore tested the hypothesis that a reduction in the amounts of active PAKs might contribute to the effects of glaucarubinone on the growth of pancreatic cancer cells. Our observation that treatment with glaucarubinone reduced the amounts of active PAK1 and PAK4 in human MiaPaCa-2 cells in vitro (Fig. 3A&B) indicates that glaucarubinone reduced pancreatic cancer cell proliferation and migration at least partly through inhibition of pathways involving PAK1 and PAK4.
Further investigation of the mechanism by which glaucarubinone regulates the amounts of active PAKs is clearly warranted. Although gemcitabine itself did not affect the amounts of either active PAK1 or PAK4, in combination with glaucarubinone it caused a significantly greater reduction in the amounts of active PAK1 and PAK4 than that caused by glaucarubinone alone in both MiaPaCa-2 and PANC-1 cells (Fig. 3A-D) . This reduction likely contributes to the synergistic inhibition of pancreatic cancer cell growth that results from combined treatment with gemcitabine and glaucarubinone.
Although glaucarubinone decreased the activity of PAK1, it did not effects the activities of either ERK or AKT (data not shown), which was different to our previous report that PAK1
konckdown suppressed colorectal cancer cell growth via inactivation of both ERK and AKT [19] . The discrepancy between the observation with pancreatic cancer cells and our previous observations with colorectal cancer cells may be caused by 1) different cancer types, pancreatic vs colorectal, or 2) different cell lines as inhibition of PAK1 suppressed colorectal cancer (CRC) cell growth and survival by inactivation of ERK and AKT in DLD1 [19] , but not in HCT116 [24] .
Among the three pancreatic cell lines used in this study, MiaPaCa-2 was the most sensitive, and PAN02 the least sensitive, to glaucarubinone (Table 1) . It may be more than coincidental that MiaPaCa-2 cells had the lowest expression of both total and active PAK1 and PAN02 cells the highest (Fig.1D) . Although the PAK4 expression levels were similar in these three lines, PAN02 cells had the highest expression of active PAK4 (Fig.1E) . In fact the IC 50 values for inhibition of proliferation by glaucarubinone were significantly correlated with the amount of pPAK4 (Fig. 1G) , and the correlation in the case of pPAK1 (Fig. 1F) Gemcitabine has long been the first-line chemotherapeutic agent in pancreatic cancer.
However, a large number of patients do not respond to the drug due to both intrinsic and acquired resistance. To improve the efficacy, systemically administered gemcitabine has been combined with a second cytotoxic agent, such as a platinum analogue, fluoropyrimidine, or a targeted cytotoxic agent [25] . A recent meta-analysis including 26 high-quality randomized trials comparing gemcitabine mono-therapy and combination therapy has demonstrated that gemcitabine-based combination therapy provides a modest improvement of survival, but is associated with increased toxicity compared with gemcitabine mono-therapy. [26] . Our findings that glaucarubinone and gemcitabine synergistically inhibited pancreatic cancer cell growth in vitro and in vivo, at least in part via inhibition of pathways involving PAK1 and PAK4, could provide a new alternative for pancreatic cancer therapy. The effect of glaucarubinone or gemcitabine on pancreatic cancer cell proliferation was determined using a 3 H-thymidine-incorporation assay ( Figure 1A ). The effect of glaucarubinone on pancreatic cancer cell migration/invasion was measured using a Boyden Chamber assay ( Figure 1B) . Values are the mean ± SEM from at least 3 independent experiments. All data represent mean ± SEM, summarised from three independent experiments.* p < 0.05; ** p < 0.01; *** p < 0.001; compared to control, and # p < 0.05; ## p < 0.01; ### p < 0.001; compared to the corresponding gemcitabine treatment. week-old SCID mice, and the animals were treated with saline [28] , glaucarubinone (Glau), gemcitabine (Gem), or the combination (GG), as described in the Figure 4 legend. The amounts of total PAK1 and active phospho-PAK1 (pPAK1) (A, C) or total PAK4 and active phospho-PAK4 (pPAK4) (B, D) were determined in extracts from excised MiaPaCa-2 (A, B)
Figure legends
or PANC-1 (C, D) tumors by Western blotting using appropriate antibodies. Variations in protein loading were corrected by GAPDH expression, and the corrected pPAK1/PAK1 or pPAK4/PAK4 ratios from untreated control tumors [28] were taken as 100%. The data represent mean + SEM, summarised from 5 mice for each group. * p<0.05; ** p<0.01 compared to control. # p<0.05 compared to treatment with glaucarubinone. 
